Cited 12 times in
Effect of Combined Bevacizumab and Temozolomide Treatment on Intramedullary Spinal Cord Tumor
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤도흠 | - |
dc.contributor.author | 하윤 | - |
dc.contributor.author | 곽소정 | - |
dc.contributor.author | 김긍년 | - |
dc.contributor.author | 안성수 | - |
dc.contributor.author | 양문술 | - |
dc.date.accessioned | 2015-01-06T17:25:34Z | - |
dc.date.available | 2015-01-06T17:25:34Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0362-2436 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/99956 | - |
dc.description.abstract | STUDY DESIGN: C6 glioma cells and an intramedullary spinal cord tumor model were used to evaluate the effect of bevacizumab (Avastin) or temozolomide (TMZ). OBJECTIVE: In this study, we hypothesized that treatment with bevacizumab accelerates the therapeutic effect of TMZ on intramedullary gliomas in an animal model. SUMMARY OF BACKGROUND DATA: Recently therapies for the management of intramedullary malignant gliomas include surgery, chemotherapy, and radiotherapy. Concurrent or adjuvant TMZ has been considered an emerging new treatment for intramedullary malignant gliomas; however, high-dose application of TMZ has limitation of side effect. METHODS: C6 glioma cells were injected into the T5 level of the spinal cord, and TMZ and bevacizumab were administered 5 days after C6 inoculation (n = 7 for each group). Tumor size was analyzed using histology and magnetic resonance imaging at 13 days after tumor inoculation. RESULTS: Histological analyses and magnetic resonance imaging findings showed that combined treatment with TMZ and bevacizumab reduced tumor mass. The tumor volume of control group was 2.8-fold higher than combined therapy (P < 0.05). Neurological outcomes demonstrated that combined therapy improved hind limb function more than TMZ-alone group or control group (P < 0.05). CONCLUSION: This study shows that bevacizumab could be useful in combination with TMZ to increase the therapeutic benefits of TMZ for intramedullary spinal cord tumors. LEVEL OF EVIDENCE: N/A. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | E65~E73 | - |
dc.relation.isPartOf | SPINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Dacarbazine/administration & dosage | - |
dc.subject.MESH | Dacarbazine/analogs & derivatives | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Rats, Sprague-Dawley | - |
dc.subject.MESH | Spinal Cord Neoplasms/drug therapy* | - |
dc.subject.MESH | Spinal Cord Neoplasms/pathology* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Effect of Combined Bevacizumab and Temozolomide Treatment on Intramedullary Spinal Cord Tumor | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학) | - |
dc.contributor.googleauthor | So-Jung Gwak | - |
dc.contributor.googleauthor | Sung Su An | - |
dc.contributor.googleauthor | Moon Sul Yang | - |
dc.contributor.googleauthor | Eunhae Joe | - |
dc.contributor.googleauthor | Dong-Hyun Kim | - |
dc.contributor.googleauthor | Do Heum Yoon | - |
dc.contributor.googleauthor | Keung Nyun Kim | - |
dc.contributor.googleauthor | Yoon Ha | - |
dc.identifier.doi | 10.1097/BRS.0000000000000070 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02546 | - |
dc.contributor.localId | A04255 | - |
dc.contributor.localId | A00168 | - |
dc.contributor.localId | A00331 | - |
dc.contributor.localId | A02235 | - |
dc.contributor.localId | A02286 | - |
dc.relation.journalcode | J02674 | - |
dc.identifier.eissn | 1528-1159 | - |
dc.identifier.pmid | 24158177 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00007632-201401150-00002&LSLINK=80&D=ovft | - |
dc.subject.keyword | bevacizumab | - |
dc.subject.keyword | temozolomide | - |
dc.subject.keyword | intramedullary spinal cord tumor | - |
dc.contributor.alternativeName | Yoon, Do Heum | - |
dc.contributor.alternativeName | Ha, Yoon | - |
dc.contributor.alternativeName | Gwak, So Jung | - |
dc.contributor.alternativeName | Kim, Keung Nyun | - |
dc.contributor.alternativeName | An, Sung Su | - |
dc.contributor.alternativeName | Yang, Moon Sool | - |
dc.contributor.affiliatedAuthor | Yoon, Do Heum | - |
dc.contributor.affiliatedAuthor | Ha, Yoon | - |
dc.contributor.affiliatedAuthor | Gwak, So Jung | - |
dc.contributor.affiliatedAuthor | Kim, Keung Nyun | - |
dc.contributor.affiliatedAuthor | An, Sung Su | - |
dc.contributor.affiliatedAuthor | Yang, Moon Sool | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 39 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 65 | - |
dc.citation.endPage | 73 | - |
dc.identifier.bibliographicCitation | SPINE, Vol.39(2) : 65-73, 2014 | - |
dc.identifier.rimsid | 53912 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.